Testimony
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a October 17, 2018 joint meeting of the FDA Gastrointestinal Drugs Advisory Committee to discuss approval of prucalopride: The International Foundation for Gastrointestinal Disorders (IFFGD) commends the FDA on its commitment to […]
Testimony
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Department of Defense (DoD) in connection with a January 10, 2019 meeting of the TRICARE Beneficiary Advisory Panel (BAP) regarding the Uniform Formulary and, specifically, review of gastrointestinal agents: The International Foundation for Gastrointestinal Disorders (IFFGD) commends TRICARE and the […]
Testimony
IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with an October 16, 2012 meeting of the Gastrointestinal Drugs Advisory Committee to consider the new drug application (NDA) 203441 by NPS Pharmaceuticals for the drug with the proposed trade name GATTEX® (teduglutide) for the treatment of adult patients with […]
Testimony
IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with a January 11, 2012 meeting of the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee to consider the premarket approval of the LINX Reflux Management System for the treatment of gastroesophageal reflux disease (GERD): On behalf […]
News Article
MOUNT PLEASANT, S.C., Dec. 1, 2025 /PRNewswire/ — This December for Constipation Awareness Month, IFFGD is shedding a light on common causes, prevention, and treatments. As well as promoting healthy conversations and lifestyle habits to support bowel movements. Constipation affects millions, approximately 1 out of every 6-7 people worldwide and annually leading to more than 1.5 million […]
Testimony
The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Food and Drug Administration (FDA) in connection with a October 18, 2018 joint meeting of the FDA Gastrointestinal Drugs Advisory Committee and Risk Management Advisory Committee to discuss the reintroduction of Zelnorm: The International Foundation for Gastrointestinal Disorders (IFFGD) […]
Testimony
IFFGD President, Ceciel Rooker, submitted the following written statement to the House and Senate Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies regarding Fiscal Year (FY) 2020 appropriations for medical research and public health programs. April 9, 2019 STATEMENT OF CECIEL T. ROOKER PRESIDENT INTERNATIONAL FOUNDATION FOR […]
The International Foundation for Gastrointestinal Disorders (IFFGD) is now accepting applications for the IFFGD 2026 Preceptorship Award. At IFFGD, our mission is deeply patient-centered — we are committed to improving the lives of those affected by gastrointestinal (GI) disorders. This award supports that mission by investing in the next generation of clinicians and researchers who […]
The International Foundation for Gastrointestinal Disorders (IFFGD) is now accepting applications and nominations for the IFFGD 2026 Travel Awards. These awards recognize and support early-career clinicians and researchers dedicated to advancing understanding and treatment of functional gastrointestinal (GI) and motility disorders. Learn more about the IFFGD Nancy and Bill Norton Research Program About the IFFGD […]
The International Foundation for Gastrointestinal Disorders (IFFGD) is pleased to announce that we are seeking applications for our 2026 research grant. The mission of IFFGD is patient oriented. Our goal is to fund high-quality research. Learn more about the IFFGD Nancy and Bill Norton Research Program About the 2026 GI Research Grant One grant award […]